FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3174681944> ?p ?o ?g. }

• W3174681944 endingPage "e470" @default.
• W3174681944 startingPage "e469" @default.
• W3174681944 abstract "Among individuals with haemophilia, the inherited X-linked disorder caused by deficient factor VIII or factor IX and characterised by spontaneous and traumatic bleeding in joints and the body cavity, the major goal of treatment is prevention of bleeding or prophylaxis. Prophylaxis with factor concentrate is known to reduce the number of bleeds and improve joint health, mobility, and quality of life, 1 Manco-Johnson MJ Abshire TC Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007; 357: 535-544 Crossref PubMed Scopus (1359) Google Scholar and pharmacokinetic studies have found that, although increasing the time above factor levels of 1% substantially reduces bleeds, 2 Collins PW Blanchette VS Fischer K et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009; 7: 413-420 Crossref PubMed Scopus (245) Google Scholar maintaining levels of 15% eliminates bleeds. 3 den Uijl IE Fischer K Van Der Bom JG Grobbee DE Rosendaal FR Plug I Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia. 2011; 17: 41-44 Crossref PubMed Scopus (126) Google Scholar Because compliance is the best determinant of factor VIII and bleeding, 2 Collins PW Blanchette VS Fischer K et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009; 7: 413-420 Crossref PubMed Scopus (245) Google Scholar efforts to reduce dose frequency by improving half-life led to the development of extended half-life factor concentrate by Fc-fusion, albumin fusion, and pegylation technologies. Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trialAlthough perioperative pharmacokinetic-guided dosing is safe, it leads to similar perioperative factor VIII consumption when compared with standard treatment. However, pharmacokinetic-guided dosing showed an improvement in obtaining factor VIII concentrations within the desired perioperative factor VIII range. These findings provide support to further investigation of pharmacokinetic-guided dosing in perioperative haemophilia care. Full-Text PDF" @default.
• W3174681944 created "2021-07-05" @default.
• W3174681944 creator A5019518672 @default.
• W3174681944 date "2021-07-01" @default.
• W3174681944 modified "2023-10-17" @default.
• W3174681944 title "Optical or optimal conclusion: pharmacokinetic-guided dosing in haemophilia" @default.
• W3174681944 cites W1678213225 @default.
• W3174681944 cites W2106173868 @default.
• W3174681944 cites W2133535613 @default.
• W3174681944 cites W2167801052 @default.
• W3174681944 cites W2565753485 @default.
• W3174681944 cites W2600562065 @default.
• W3174681944 cites W2804969681 @default.
• W3174681944 cites W3176224733 @default.
• W3174681944 doi "https://doi.org/10.1016/s2352-3026(21)00163-0" @default.
• W3174681944 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34171272" @default.
• W3174681944 hasPublicationYear "2021" @default.
• W3174681944 type Work @default.
• W3174681944 sameAs 3174681944 @default.
• W3174681944 citedByCount "1" @default.
• W3174681944 countsByYear W31746819442023 @default.
• W3174681944 crossrefType "journal-article" @default.
• W3174681944 hasAuthorship W3174681944A5019518672 @default.
• W3174681944 hasConcept C126322002 @default.
• W3174681944 hasConcept C17744445 @default.
• W3174681944 hasConcept C187212893 @default.
• W3174681944 hasConcept C199539241 @default.
• W3174681944 hasConcept C2777232031 @default.
• W3174681944 hasConcept C2777288759 @default.
• W3174681944 hasConcept C2778385053 @default.
• W3174681944 hasConcept C2779473830 @default.
• W3174681944 hasConcept C3020646304 @default.
• W3174681944 hasConcept C3020774429 @default.
• W3174681944 hasConcept C71924100 @default.
• W3174681944 hasConcept C83867959 @default.
• W3174681944 hasConcept C95190672 @default.
• W3174681944 hasConceptScore W3174681944C126322002 @default.
• W3174681944 hasConceptScore W3174681944C17744445 @default.
• W3174681944 hasConceptScore W3174681944C187212893 @default.
• W3174681944 hasConceptScore W3174681944C199539241 @default.
• W3174681944 hasConceptScore W3174681944C2777232031 @default.
• W3174681944 hasConceptScore W3174681944C2777288759 @default.
• W3174681944 hasConceptScore W3174681944C2778385053 @default.
• W3174681944 hasConceptScore W3174681944C2779473830 @default.
• W3174681944 hasConceptScore W3174681944C3020646304 @default.
• W3174681944 hasConceptScore W3174681944C3020774429 @default.
• W3174681944 hasConceptScore W3174681944C71924100 @default.
• W3174681944 hasConceptScore W3174681944C83867959 @default.
• W3174681944 hasConceptScore W3174681944C95190672 @default.
• W3174681944 hasIssue "7" @default.
• W3174681944 hasLocation W31746819441 @default.
• W3174681944 hasOpenAccess W3174681944 @default.
• W3174681944 hasPrimaryLocation W31746819441 @default.
• W3174681944 hasRelatedWork W1995822104 @default.
• W3174681944 hasRelatedWork W2005719195 @default.
• W3174681944 hasRelatedWork W2067082011 @default.
• W3174681944 hasRelatedWork W2101928171 @default.
• W3174681944 hasRelatedWork W2138001653 @default.
• W3174681944 hasRelatedWork W2166990743 @default.
• W3174681944 hasRelatedWork W2474677341 @default.
• W3174681944 hasRelatedWork W3113163854 @default.
• W3174681944 hasRelatedWork W3155450815 @default.
• W3174681944 hasRelatedWork W4233505807 @default.
• W3174681944 hasVolume "8" @default.
• W3174681944 isParatext "false" @default.
• W3174681944 isRetracted "false" @default.
• W3174681944 magId "3174681944" @default.
• W3174681944 workType "article" @default.